Atherosclerosis and uremia: The importance of non-traditional risk factors;Atherosklerose und urämie: Die bedeutung nicht-traditioneller risikofaktoren

Wiener Klinische Wochenschrift

Volumn 115, Issue 7-8, 2003, Pages 220-234

  Hörl, Walter H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Asymmetric dimethylarginine; Carbonyl stress; Homocysteine; Hypertension; Insulin resistance; Oxidative stress; Phosphorus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED LIPOXIDATION END PRODUCT; ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; PHOSPHORUS; UNCLASSIFIED DRUG;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CHRONIC KIDNEY FAILURE; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; OXIDATIVE STRESS; REVIEW; RISK FACTOR; UREMIA; VASCULAR SMOOTH MUSCLE;

EID: 0037599259     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03040320     Document Type: Review

References (182)

1. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 [Suppl]: S112-S119
2. Lindner A, Charra B, Sherrard DJ, Scribner BH (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697-701
3. London GM, Guérin AP, Marchais SJ, Pannier B, Safar ME, et al (1996) Cardiac and arterial interactions in endstage renal disease. Kidney Int 50: 600-608
4. Blacher J, Guérin AP, Pannier B, Marchais SJ, Safer ME, London GM (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434-2439
5. Guérin AP, London GM, Marchais SJ, Metivier F (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 15: 1014-1021
6. Ross R (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126
7. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, et al (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49: 1304-1313
8. Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, et al (2001) Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 38: 537-546
9. Shoji T, Emoto M, Tabata T, Kimoto E, Shinohara K, et al (2002) Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int 61: 2187-2192
10. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, et al (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106: 100-105
11. Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, et al (2000) Atherosclerotic cardiovascular disease in chronic hemodialysis patients. Kidney Int 58: 353-362
12. Ridker PM (1999) Evaluating novel cardiovascular risk factors: can we do better predict heart attacks? Ann Intern Med 130: 933-937
13. Zimmermann J, Herrlinger S, Pruy A, et al (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55: 648-658
14. Yeun JY, Levine RA, Mantadilok V, et al (2000) C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 35: 469-476
15. Torzewski J, Torzewski M, Bowyer DE, et al (1998) C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18: 1386-1392
16. Bhakdi S, Torzewski M, Klouche M, et al (1999) Binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol 19: 2348-2354
17. Cermak J, Key NS, Bach RR, et al (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82: 513-520
18. Nakagomi A, Freedman SB, Geczy CL (2000) Interferongamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: relationship with age, sex, and hormone replacement treatment. Circulation 101: 1785-1791
19. Sethi D, Muller BR, Brown EA, et al (1998) C-reactive protein in haemodialysis patients with dialysis arthropathy. Nephrol Dial Transplant 3: 269-271
20. Haubitz M, Brunkhorst R, Wrenger E, et al (1996) Chronic induction of C-reactive protein by hemodialysis, but not by peritoneal dialysis therapy. Perit Dial Int 16: 158-162
21. Haubitz M, Schulze M, Koch KM, et al (1990) Increase of C-reactive protein serum values following haemodialysis. Nephrol Dial Transplant 5: 500-503
22. Schouten WEM, Grooteman MPC, van Houte A-J, et al (2000) Effects of dialyser and dialysate on the acute phase reaction in clinical bicarbonate dialysis. Nephrol Dial Transplant 15: 379-384
23. Panichi V, Migliori M, de Pietro S, et al (2000) Plasma C- reactive protein in hemodialysis patients: a cross sectional, longitudinal clinical survey. Blood Purif 18: 30-36
24. Libetta C, de Nicola L, Rampino T, et al (1996) Inflammatory effects of peritoneal dialysis: evidence of systemic monocyte activation. Kidney Int 49: 506-511
25. Bergström J, Lindholm B (1998) Malnutrition, cardiac disease, and mortality: An integrated point of view. Am J Kidney Dis 32: 834-841
26. Lowrie EG (1998) Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 32 [Suppl 4]: S105-S112
27. Ikizler TA, Wingard RL, Harvell J, et al (1999) Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients: a prospective study. Kidney Int 55: 1945-1951
28. CREED (Cardiovascular Risk Extended Evaluation in Dialysis Patients) Investigators (1998) C-reactive protein and atherosclerosis in dialysis patients. Nephrol Dial Transplant 13: 2710-2711
29. Stenvinkel P, Heimburger O, Paultre F, et al (1999) Strong association between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int 55: 1899-1911
30. Arici M, Walls J (2001) End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 59: 407-414
31. Hasselwander O, Young IS (1998) Oxidative stress in chronic renal failure. Free Rad Res 29: 1-11
32. Galli F, Canestrari F, Bellomo G (1999) Physiopathology of the oxidative stress and its implications in uremia and dialysis. Contrib Nephrol 127: 1-31
33. Mimic-Oka J, Simic T, Djukanovic I, Davicevic Z (1999) Alteration in plasma antioxidant capacity in various degrees of chronic renal failure. Clin Nephrol 51: 233-241
34. Lim PS, Wang NP, Lu TC, Wang TH, Hsu WM, et al (2001) Evidence for alterations in circulating low-molecular weight antioxidants and increased lipid peroxidation in smokers on hemodialysis. Nephron 88: 127-133
35. Morena M, Cristol JP, Bosc JY, Tetta C, Forret G, et al (2002) Convective and diffuse losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant 17: 422-427
36. Miyata T, van Ypersele C, Kurokawa K, Baynes JW (1999) Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55: 389-399
37. Raj DSC, Choudhury D, Welbourne C, Levi M (2000) Advanced glycation end products: a nephrologist's perspective. Am J Kidney Dis 35: 365-380
38. Wittko-Sarsat V, Friedlander M, Nguyen-Khoa T, Capeillere-Blandin C, Nguyen AT, et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161: 2524-2532
39. Schinzel R, Münch G, Heidland A, Sebekova K (2001) Advanced glycation end products in end-stage renal disease and their removal. Nephron 87: 295-303
40. Miyata T, Kurokawa K, van Ypersele de Strihou C (2000) Advanced glycation and lipoxidation end products: role of carbonyl compound generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 11: 1744-1752
41. Miyata T, Inagi R, Asahi K, Yamada Y, Horie K, et al (1998) Generation of protein carbonyls by glycoxidation and lipoxidation reactions with autoxidation products of ascorbic acid and polyunsaturated fatty acids. FEBS Lett 437: 24-28
42. Meng J, Sakata N, Imanaga Y, Tachikawa Y, Chihara J, Takebayashi S (1999) Evidence for a link between glycoxidation and lipoperoxidation in patients with chronic renal failure. Clin Nephrol 51: 280-289
43. Niwa T, Tsukushi S (2001) 3-Desoxyglucosone and AGEs in uremic complications: inactivation of glutathione peroxidase by 3-deoxyglucosone. Kidney Int 59 [Suppl 78]: S-37-S-41
44. Anderson MM, Hazen SL, Hsu FF, Heinecke JW (1997) Human neutrophils employ the myeloperoxidase-hydrogen peroxide chloride system to convert hydroxy-amino acids into glycoaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alphahydroxy and alpha, beta-unsaturated aldehydes by phagocytes at sites of inflammation. J Clin Invest 99: 424-432
45. Drüeke, T Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guérin A, et al (2002) Iron therapy, advanced oxidation protein products and carotid artery intima-media thickness in end-stage renal disease. Circulation 106: 2212-2217
46. Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1996) Advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271: 9982-9986
47. Meng J, Sakata N, Imanaga Y, Takebayashi S, Nagai R, Horiuchi S (2001) Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: relevance to glycoxidation damage. Nephron 88: 30-35
48. Schwedler SB, Metzger T, Schinzel R, Wanner C (2002) Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62: 301-310
49. Himmelfarb J, McMenamin E, McMonagle E (2002) Plasma aminothiol oxidation in chronic hemodialysis patients. Kidney Int 61: 705-716
50. Wilcken DE, Gupta VJ (1979) Sulphur containing amino acids in chronic renal failure with particular reference to homocystine and cysteine-homocysteine mixed disulphide. Eur J Clin Invest 9: 301-307
51. Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, Hörl WH, Sunder-Plassmann G (1997) Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients. Kidney Int 52: 517-523
52. Vychytil A, Födinger M, Wölfl G, Enzenberger, B, Auinger M, Prischl F, Buxbaum M, Wiesholzer M, Mannhalter C, Hörl WH, Sunder-Plassmann G (1998) Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int 53: 1775-1782
53. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H (1996) The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 56: 41-46
54. Robinson K, Gupta A, Dennis V, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen DW (1996) Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 94: 2743-2748
55. McGregor DO, Dellow WJ, Lever M, George PM, Robson RA, Chambers ST (2001) Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. Kidney Int 59: 2267-2272
56. Skoupy S, Födinger M, Veitl M, Perschl A, Puttinger H, Rohrer C, Schindler K, Vychytil A, Hörl WH, SunderPlassmann G (2002) Riboflavin is a determinant of total homocysteine plasma concentrations in end-stage renal disease patients. J Am Soc Nephrol 13: 1331-1337
57. Wilcken DE, Wilcken B (1976) The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 57: 1079-1082
58. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I (1991) Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl Med 324: 1149-1155
59. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274: 1049-1057
60. Danesh J, Lewington S (1998) Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 5: 229-232
61. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP, et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10: 111-113
62. Klerk M, Verhoef P, Clarke R (2002) MTHFR C677C>T polymorphism and risk of coronary heart disease: metaanalysis of 40 studies. JAMA 288: 2023-2031
63. Homocysteine Studies Collaboration (2002) Homocysteine and risk of ischemic heart disease and stroke: metaanalysis. JAMA 288: 2015-2022
64. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R (1996) Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine and risk of myocardial infarction in US physicians. Circulation 94: 2410-2416
65. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H (1996) Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (>40 μmol/l). The Hordaland Homocysteine Study. J Clin Invest 98: 2174-2183
66. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J (1997) A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. Stroke 28: 1739-1743
67. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, Maemura K, Shindo T, Minamino T, Ohno M, Yamaoki K, Ogasawara K, Aizawa T, Suzuki S, Yazaki Y (1997) Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95: 2032-2036
68. Van Bockxmeer FM, Mamotte CDS, Vaikaran SD, Taylor RR (1997) Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 95: 21-23
69. Brattstrom L, Wilcken DEL, Ohrvik J, Brudin L (1998) Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 98: 2520-2526
70. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Kitamura K, Yazaki Y (1998) Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. Arterioscler Thromb Vasc Biol 18: 1465-1469
71. 12 and on the risk of premature atherosclerosis. Atherosclerosis 141: 161-166
72. Harmon DL, Doyle RM, Meleady R, Doyle M, Shields DC, Barry R, Coakley D, Graham IM, Whitehead AS (1999) Genetic analysis of the thermolabile variant of 5,10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. Arterioscler Thromb Vasc Biol 19: 208-211
73. Lim P-S, Hung W-R, Wei Y-H (2001) Polymorphism in methyltetrahydrofolate reductase gene: its impact on plasma homocysteine levels and carotid atherosclerosis in ESRD patients receiving hemodialysis. Nephron 87: 249-256
74. Haviv YS, Shpichinetsky V, Goldschmidt N, Abou Atta I, Ben-Yehuda A, Friedman G (2002) The common mutations C677T and A1298C in the human methylenetetrahydrofolate reductase gene are associated with hyperhomocysteinemia and cardiovascular disease in hemodialysis patients. Nephron 92: 120-126
75. Dudman NP (1999) An alternative view of homocysteine. Lancet 354: 2072-2074
76. Brattstrom L, Wilcken DE (2000) Homocysteine and cardiovascular disease: cause or effects? Am J Clin Nutr 72: 315-323
77. Starkebaum G, Haarlan JM (1986) Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 77: 1370-1376
78. Celermajer DS, Sorensen K, Ryalls M, Robinson J, Thomas O, Leonard JV, Deanfield JE (1993) Impaired endothelial function occurs in the systemic arteries of children with homozygous homocystinuria but not in their heterozygous parents. J Am Coll Cardiol 22: 854-858
79. van Guldener C, Stehouwer CDA (2000) Hyperhomocysteinemia, vascular pathology and endothelial function. Sem Thromb Hemos 26: 281-289
80. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, Guillou J, Charpiot P, Bodard H, Ghiringhelli O, et al (1995) Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 91: 1161-1174
81. Kottke-Matchant K, Grenn R, Jacobsen D, Dicorleto P (1990) Subcytotoxic homocysteine increases monocyte adhesion to human aortic endothelial cells. Blood 76: 511 (abstract)
82. Willems FF, Aengevaeren W, Blom HJ, et al (2003) Coronary endothelial dysfunction is related to hyperhomocysteinemia. Homocysteine is related to endothelial dysfunction. Eur J Clin Invest (in press)
83. Willems FF, Aengevaeren WMA, Boers GH, et al (2002) Coronary endothelial function in hyperhomocysteinemia: improvement after treatment with folic acid and cobalamin in patients with coronary artery disease. J Am Coll Cardiol 40: 766-772
84. Kanani PM, Sinkey CA, Browning RL, Allaman M, Knapp HR, Haynes WG (1999) Role of oxidant stress in endothelial dysfunction produced by experimental hyperhomocyst(e)inemia in humans. Circulation 100: 1161-1168
85. Nappo F, De Rosa N, Marfella R, De Lucia D, Ingrosso D, Perna AF, Farzati B, Giugliano D (1999) Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA 281: 2113-2118
86. Mujumdar VS, Aru GM, Tyagi SC (2001) Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82: 491-500
87. Blacher J, Demuth K, Guerin AP, Safar ME, Moatti N, London GM (1998) Influence of biochemical alterations on arterial stiffness in patients with end stage renal disease. Arterioscler Thromb Vasc Biol 18: 535-541
88. Blacher J, Demuth K, Guerin AP, Vadez C, Moatti N, Safar ME, London GM (1999) Association between plasma homocysteine concentrations and cardiac hypertrophy in end-stage renal disease. J Nephrol 12: 248-255
89. Bostom AG, Shemin D, Verhoef P, Nadeau MR, Jacques PF, Selhub J, Dworkin L, Rosenberg IH (1997) Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study. Arterioscler Thromb Vasc Biol 17: 2554-2558
90. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, Robinson K, Dennis VW (1998) Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 97: 138-141
91. Dierkes J, Domrose U, Westphal S, Ambrosch A, Bosselmann HP, Neumann KH, Luley C (2000) Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 102: 1964-1969
92. Mallamaci F, Zoccali C, Tripepi G (2002) Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 61: 609-614
93. Refsum H, Ueland PM, Nygard O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49: 31-62
94. Bortolotto LA, Safar ME, Billaud E, Lacroix C, Asmar R, London GM, Blacher J (1999) Plasma homocysteine, aortic stiffness, and renal function in hypertensive patients. Hypertension 34: 837-842
95. Perry IJ (1999) Homocysteine, hypertension and stroke. J Hum Hypertens 13: 289-293
96. Perry IJ (1999) Homocysteine and risk of stroke. J Cardiovasc Risk 6: 235-240
97. Lin N, Chen Y-F, Zou A-P (2002) Implications of hyperhomocysteinemia in glomerular sclerosis in hypertension. Hypertension 39: 443-448
98. Dudman NP, Hicks C, Wang J, Wilcken DE (1991) Human arterial endothelial cell detachment in vitro: its promotion by homocysteine and cysteine. Atherosclerosis 91: 77-83
99. Woo KS, Chook P, Lolin YI, Cheung AS, Chan LT, Sun YY, Sanderson JE, Metreweli C, Celermajer DS (1997) Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96: 2542-2544
100. Chambers JC, McGregor A, Jean-Marie J, Kooner JS (1998) Acute hyperhomocysteinemia and endothelial dysfunction. Lancet 351: 36-37
101. Hajjar KA (1993) Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest 91: 2873-2879
102. Lentz SR, Sadler JE (1991) Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 88: 1906-1914
103. Lentz SR, Sadler JE (1993) Homocysteine inhibits von Willebrand factor processing and secretion by preventing transport from the endoplasmic reticulum. Blood 81: 683-689
104. Rodgers GM, Conn MT (1990) Homocysteine, an atherogenic stimulus reduces protein C activation by arterial and venous endothelial cells. Blood 75: 895-901
105. Harpel PC, Chang VT, Borth W (1992) Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 89: 10193-10197
106. Kunz K, Petitjean P, Lisri M, Chantrel F, Koehl C, Wiesel ML, Cazenave JP, Moulin B, Hannedouche TP (1999) Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: is homocyst(e)ine the missing link? Nephrol Dial Transplant 14: 1934-1942
107. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ (1999) Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 29: 657-662
108. Wilmink HW, Stroes ES, Erkelens WD, Gerritsen WB, Wever R, Banga JD, Rabelink TJ (2000) Influence of folic acid on postprandial endothelial dysfunction. Arterioscler Thromb Vasc Biol 20: 185-188
109. Thamyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN (2000) Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure? Circulation 102: 871-875
110. Van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD (1998) Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: no change in endothelial function after long-term therapy. Perit Dial Int 18: 282-289
111. Levine GN, Frei B, Koulouris SN, Gerhard MD, Keaney JF Jr, Vita JA (1996) Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93: 1107-1113
112. Ting HH, Timimi FK, Haley EA, Roddy MA, Ganz P, Creager MA (1997) Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 95: 2617-2622
113. Chambers JC, McGregor A, Jean-Marie J, Obeid OA, Kooner JS (1999) Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia: an effect reversible with vitamin C therapy. Circulation 99: 1156-1160
114. Outinen PA, Sood SK, Pfeifer SI, Pamidi S, Podor TJ, Li J, Weitz JI, Austin RC (1999) Homocysteine-induced endoplasmatic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood 94: 959-967
115. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR (2000) Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 20: 1557-1564
116. Suliman ME, Qureshi AR, Barany P, Stenvinkel P, Filho JC, Anderstam B, Heimburger O, Lindholm B, Bergström J (2000) Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57: 1727-1735
117. Suliman ME, Barany P, Filho JC, Qureshi AR, Stenvinkel P, Heimburger O, Anderstam B, Lindholm B, Bergström J (2002) Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease. Nephrol Dial Transplant 17: 1050-1056
118. Suliman ME, Stenvinkel P, Barany P, Heimburger O, Anderstam B, Lindholm B (2002) No association between plasma total homocysteine (tHcy) in end-stage renal disease (ESRD) patients (pts). J Am Soc Nephrol 13: 466A
119. Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN (2000) Abnormalities of endothelial function in patients with predialysis renal failure. Heart 83: 205-209
120. Joannides R, Bakkali EH, Le Roy F, Rivault O, Godin M, Moore N, Fillastre JP, Thuillez C (1997) Altered flowdependent vasodilatation of conduit arteries in maintenance haemodialysis. Nephrol Dial Transplant 12: 2623-2628
121. Van Guldener C, Lambert J, Janssen MJ, Donker AJ, Stehouwer CD (1997) Endothelium-dependent vasodilation and distensibility of large arteries in chronic haemodialysis patients. Nephrol Dial Transplant 12: 14-18
122. Passauer J, Büssemaker E, Range U, Plug M, Gross P (2000) Evidence in vivo showing increase of baseline nitric oxide generation and impairment of endothelium dependent vasodilatation in normotensive patients on chronic hemodialysis J Am Soc Nephrol 11: 1726-1734
123. Vallance P, Leone A, Calver A, Collier J, Moncada S (1992) Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339: 572-575
124. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E (1996) Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11: 2449-2452
125. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 8: 1437-1442
126. Schmidt RJ, Domico J, Samsell LS,Yokota S, Tracy TS, Sorkin MI, Engels K, Baylis C (1999) Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 34: 228-234
127. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10: 594-600
128. Zoccali C, Bode-Böger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger R (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358: 2113-2117
129. Zoccali C, Benedetto FA, Maas R, et al (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13: 490-496
130. Kielstein JT, Böger RH, Bode-Böger SM, Frölich JC, Haller H, Ritz E, Fliser D (2002) Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13: 170-176
131. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, et al (1999) Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation 99: 1141-1146
132. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20: 2032-2037
133. Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 98: 1842-1847
134. Moeslinger T, Friedl R, Volf I, Brunner M, Baran H, Koller E, Spieckermann PG (1999) Urea induces macrophage proliferation by inhibition of inducible nitric oxide synthesis. Kidney Int 56: 581-588
135. Moeslinger T, Spieckermann PG (2001) Urea-induced inducible nitric oxide synthase inhibition and macrophage proliferation. Kidney Int 59 [Suppl 78]: S2-S8
136. Giachelli CM (1999) Ectopic calcification: gathering hard facts about soft tissue mineralization. Am J Pathol 154: 671-675
137. Alfrey AC, Ibels LS (1978) Role of phosphate and pyrophosphate in soft tissue calcification. Adv Exp Med Biol 103: 187-193
138. Block GA, Port FK (2000) Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 1236-1237
139. Block GA, Hulbert ST, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31: 607-617
140. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, et al (2000) Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478-1483
141. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87: e10-e17
142. Drüeke TB, Rostand SG (2002) Progression of vascular calcification in uraemic patients: can it be stopped? Nephrol Dial Transplant 17: 1365-1368
143. Shearer MJ (2000) Role of vitamin K and gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care 3: 433-438
144. Ketteler M, Bongratz P, Westenfeld R, Wildberger EJ, Mahnken A, Böhm R, et al (2003) Association of fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361: 827-833
145. Westenfeld R, Heiss A, Ketteler M, Floege J, Schwarz A, Jahnen-Dechent W (2002) Calciphylaxis is linked to systemic deficiency of the calcification inhibitor Ahsg/fetuin. J Am Soc Nephrol 13: 219A
146. Massry SG, Smogorzewski M (1994) Mechanisms through which parathyroid hormone mediates its deleterious effects on organ function in uremia. Semin Nephrol 14: 219-231
147. Kawagishi T, Nishizawa Y, Konishi T, Kawasaki K, Emoto M, et al (1995) High-resolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 48: 820-826
148. Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 170-176
149. Hörl WH (2003) Renal osteodystrophy: role of calcimimetics. Am J Kidney Dis 41 [Suppl 2]: S104-107
150. Jono S, Nishizawa Y, Shioi A, Morii H (1997) Parathyroid hormone-related peptide as a regulator of vascular calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 1135-1142
151. Nakayama T, Ohtsuru A, Enomoto H, Namba H, Ozeki S, et al (1994) Coronary atherosclerotic smooth muscle cells overexpress human parathyroid hormone-related peptids. Biochem Biophys Res Commun 200: 1028-1035
152. Reslerova M, Moe SM (2002) Vascular calcification in dialysis patients: pathogenesis and consequences. Am J Kidney Dis 41 [Suppl 1]: S96-S99
153. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecki K (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61: 638-647
154. Kawagishi T, Nishizawa Y, Konishi T, et al (1995) Highresolution B-mode ultrasonography in evaluation of atherosclerosis in uremia. Kidney Int 48: 820-826
155. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K (1998) Prevention of coronary heart disease in clinical practice: recommendation of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 140: 199-270
156. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2001) JAMA 285: 2486-2497
157. Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, et al (1998) Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9: 1277-1284
158. Frost PH, Havel RJ (1998) Rationale for use of non-highdensity lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 81: 26B-31B
159. Nishizawa Y, Shoji T, Kakiya R, Tahara H, Koyama H, Tabata T, Ishimura E, Miki T, Inaba M (2003) Non-highdensity lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int 61 [Suppl 84]: S117-S120
160. Shoji T, Kawagishi T, Emoto M, Maekawa K, Taniwaki H, et al (2000) Additive impacts of diabetes and renal failure on carotid atherosclerosis. Atherosclerosis 153: 257-258
161. Shoji T, Emoto M, Shinohara K, Kakiya R, Tsujimoto Y, et al (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12: 2117-2124
162. Kronenberg F, Lingenhel A, Neyer U, Lhotta K, König P, et al (2003) Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int 61 [Suppl 84]: S113-S116
163. Fukumoto M, Shoji T, Emoto M, Kawagishi T, Okuno Y, Nishizawa Y (2000) Antibodies to oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 20: 703-707
164. Hulthe J, Bokemark L, Fagerberg B (2001) Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 21: 101-107
165. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, et al (2003) The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int 61 [Suppl 84]: S128-S130
166. Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H, Koyama H, Ishimura E, Nakatani T, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y (2002) Antibody to oxidized low density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 62: 2230-2237
167. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, et al (2000) Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 36: 751-757
168. Warner MM, Guo J, Zhao Y (2001) The relationship between plasma apolipoprotein A-IV levels and coronary heart disease. Chin Med J (Engl) 114: 275-279
169. Kronenberg F, Kuen E, Ritz E, König P, Kraatz G, et al (2002) Apolipoprotein A-IV serum concentrations are elevated in mild and moderate renal failure. J Am Soc Nephrol 13: 461-469
170. Dandona P, Aljada A, Mohanty P (2002) The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45: 924-930
171. Kernan WN, Inzucchi SE, Viscolii CM, Brass LM, Bravata DM, Horwitz RI (2002) Insulin resistance and risk for stroke. Neurology 59: 809-815
172. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F (2002) Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis; the atherosclerosis risk in communities study. Diabetes 51: 3069-3076
173. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13: 1894-1900
174. Hörl MP, Hörl WH (2002) Hemodialysis-associated hypertension: pathophysiolgy and therapy. Am J Kidney Dis 39: 227-244
175. Must A, Spadano J, Coakley EH, et al (1999) The disease burden associated with overweight and obesity. JAMA 282: 1523-1529
176. Han TS, van Leer EM, Seidel JC, Lean ME (1995) Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. Br Med J 31: 1401-1405
177. Johnson DW, Herig KA, Purdie DM, et al (2000) Is obesity a favourable prognostic factor in peritoneal dialysis patients? Perit Dial Int 20: 715-721
178. Port KF, Ashby VB, Dhingra RK, et al (2002) Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 13: 1061-1066
179. Fleischmann E, Teal N, Dudley J, et al (1999) Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int 55: 1560-1567
180. London GM, Drüeke TB (1997) Atherosclerosis and arteriosclerosis in chronic renal failure. Kidney Int 51: 1678-1695
181. Zoccali C (2000) Cardiovascular risk in uremic patients: is it fully explained by classical risk factors? Nephrol Dial Transplant 15: 454-456
182. Baigent C, Burbury K, Wheeler D (2000) Premature cardiovascular disease in chronic renal failure. Lancet 356: 147-152